Company intelligence / Profile preview

Omega Therapeutics

Cambridge, Massachusetts, United Statesorpha.net ↗

Ownership: Public · OMGA
Employees: ~94
Development stage: Phase 1

Overview

Completed Phase 1 MYCHELANGELO trial of OTX-2002 showed 50% disease control rate in HCC patients, demonstrating ability to induce prespecified changes in epigenetic signatures that alter gene expression with high specificity[8][9]

Therapeutic areas: GastroenterologyCardiovascularMetabolic DisordersEndocrinologyOncology
Modalities: Programmable epigenomic mRNA medicinesepigenomic controllers (ECs)
Industry: Biotech

Drug pipeline

2 assets

OTX-2002

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Novo Nordisk (research collaboration for cardiometabolic therapies)

Financials

Market cap: $7.9M
Total revenue: $2.6M
Enterprise value: $105.7M

Beyond the preview

Go deeper on Omega Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omega Therapeutics.

Explore the full profile